Strides Pharma Science Ltd · NSE:STAR

Strides Pharma Science — Investor Presentation (November 2018)

28 slides from Strides Pharma Science's investor presentation, November 2018

  1. Slide 1: Investor Presentation, November 2018

    Investor Presentation, November 2018

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying slides (the “Presentation”), which has been prepared by the Company, has been prepared for information purposes only and is not, and is not intended to be, an offer, or solicitation of offer, or invitation or recommendation to buy or sell any securit

  3. Slide 3: Strides 1.0 delivered value. Strides 2.0 is next.

    Strides 1.0 delivered value. Strides 2.0 is next.

  4. Slide 4: Value creation over time

    Value creation over time Strategic progression, Significant value unlocked 2008-13 Today 2004-08 Value Unlock Strides 2.0 1990- − Sale of Ascent Pharma and − B2C Focus Agila Specialties 2004 − Branded generics Course − Over $2b worth of value portfolio unlocked Correction − De-levered balance sheet

  5. Slide 5: Evolution of Strides 2.0

    Evolution of Strides 2.0 Growth pivots in place with organic and inorganic strategies Re-entered Australia Acquisition of Sale of Africa generics Divestment of India Proposed merger with Apotex in through Arrow. Bolt on Universal in Africa to business and Capping branded business Australia to become

  6. Slide 6: Strongly Positioned Today

    Strongly Positioned Today STRONG B2C FOUNDATION Manufacturing Experienced Best in class Diversified Supply chain Strong R&D operations with management team Quality business model security Capability high automation Compliance Scope Infrastructure Research Portfolio Management Compliance − Well diver

  7. Slide 7: Strides 2.0 strategy is in place. Focus is on execution.

    Strides 2.0 strategy is in place. Focus is on execution. United States Australia Other Regulated – UK, Europe, South Africa Africa Institutional Business

  8. Slide 8: Execution in Play

    Execution in Play Sharpened focus across all value drivers Diversified market Technology and positioning Compliance Diversified B2C business model Highly compliant culture led by with frontend presence across technology driven quality regulated markets and Africa environment continent Experienced Ma

  9. Slide 9: Diversified market positioning

    Diversified market positioning Consumer facing formulation businesses STRIDES 2.0 Regulated Markets Africa Continent − Front end presence across − Front End focus markets of Africa, Australia, US, UK and South Africa South East Asia with a portfolio of branded generics − Strategic partnerships in ot

  10. Slide 10: Differentiated Strategy for Continued Growth

    Differentiated Strategy for Continued Growth Focused approach for each market EUROPEAN UNION UNITED STATES Driven by UK front end Own front end with a and strategic tie ups in differentiated portfolio rest of Europe AUSTRALIA Leadership position in generics and OTC Own front end in French, West and

  11. Slide 11: Growth Markets. Competitive Positioning.

    Growth Markets. Competitive Positioning.

  12. Slide 12: United States

    United States In growth phase, Anchor market for future Opportunity Business Today − $467b+ market with patent expiry of brands worth − Portfolio of 80 filed ANDAs 27 pending approval) $77.2b in the next 5 years − Strong go to market capability through own − Indian generics have 40% of volumes in US

  13. Slide 13: Strong and Efficient R&D Capability

    Strong and Efficient R&D Capability Calibrated to Version 2.0 Filings momentum to continue with 20-25 ANDA filings per year Organization Proficient Regulatory Network Modelled on Full Time Equivalence (FTE) structure Capable of developing and for improved efficiency and filing products for all incre

  14. Slide 14: In a sweet spot under new GDUFA guidelines

    In a sweet spot under new GDUFA guidelines Filing and approvals seeing strong momentum − Longer approval cycles, GDUFA PRE- Pending 1* Legacy filings (FDA backlog) backlog of ANDAs pending for approval Total Filings 30** Average approval cycles STRIDES 1.0 >60 months (Pre 2012) Pending 1 2013 Total

  15. Slide 15: Exciting growth pipeline nearing approval

    Exciting growth pipeline nearing approval Bigger products faster to market Pending Approvals Approval Majority approvals pending under timeline Robust Visibility on the pipeline GDUFA 1 Cohort 5 and GDUFA II PRE-GDUFA 40 – 60+ o 27 ANDA’s pending approval with the USFDA filed 1 mostly in cohort 5 of

  16. Slide 16: Future ready manufacturing base

    Future ready manufacturing base Highly compliant manufacturing base, capacity mapped BANGALORE INDIA BANGALORE CHENNAI, INDIA INDIA* MILAN, ITALY PUDUCHERRY, INDIA BY MANUFACTURING CAPABILITY FDF Emerging Market Facility SINGAPORE NAIROBI, KENYA Regulated Emerging Market Facility Markets Facility *J

  17. Slide 17: Technology and Compliance

    Technology and Compliance Continued focus on quality, compliance & governance Structured approach of product Emphasis on skill & competency Integrated QMS with development & lifecycle management development of employees increased effectiveness embedded with QBD LES MES TRAINING & RESEARCH QMS Fully

  18. Slide 18: Australia Generic Market Landscape

    Australia Generic Market Landscape A market with high entry barrier Attractive pharmaceutical and OTC market Ranbaxy & Others, 4% o Generic market size at $1.8b, market consolidated due Sandoz, Arrow, 24% to high cost of operation and high competitive barriers 18% o Generic substitution currently at

  19. Slide 19: Australia

    Australia Settled Strategy , poised for leadership Opportunity Business Today − Market to stay consolidated with high entry barriers − Ranks #2 by volume and #3 by revenues for new entrants − Strong OTC portfolio through Chemist’s Own OTC − Pharmacy ownership to stay independent by law, franchise op

  20. Slide 20: Strides & Apotex agree to merge in Australia

    Strides & Apotex agree to merge in Australia Getting to pole position in Australia + = LEADERSHIP Key Highlights Strategic rationale − The combination will enable Strides, through the merged business, to become the number 1 Australian generic pharmaceutical company by both volume and revenue o Arrow

  21. Slide 21: Other Regulated Markets

    Other Regulated Markets Portfolio and geographical expansion to be the key growth drivers Opportunity Business Today − The European pharmaceutical market is likely to − Diversified portfolio including Rx soft gelatin grow to $230b by 2022 capsules, sachets and oral solids in wide ranging − Growth ex

  22. Slide 22: Africa

    Africa “In Africa for Africa” theme with focus on Branded Generics Opportunity Business Today − Macro tailwinds with increased urbanization, − Footprint in 40+ countries across Sub-Saharan purchasing power and healthcare infrastructure Africa, Local medical field force with coverage of − Increasing

  23. Slide 23: Institutional Business

    Institutional Business Focus on new treatment regimens Opportunity Business Today − Market opportunity of $2.5b in terms of − Approved supplier to institutionally funded aid procurement projects and global procurement agencies like − Concentrated market with 5-6 key players holding UNITAID, PEPFAR,

  24. Slide 24: Robust Planning. Sustainable growth.

    Robust Planning. Sustainable growth.

  25. Slide 25: Strides 2.0- Continued Growth & Value Creation

    Strides 2.0- Continued Growth & Value Creation Strong Business Steady Growth Steady returns to the Foundation through Execution stakeholders − Highly compliant manufacturing − Expanding portfolio range with − Focus on generating operating base addition of differentiated and limited leverage competit

  26. Slide 26: Consolidated Financials

    Consolidated Financials Key Financial Highlights FY 18 Revenues Net Worth INR 28,576 Mn INR 26,092 Mn EBITDA and Margin Net Debt1 INR 4,369 Mn (15%) INR 17,063 Mn Adjusted PAT2 Net Debt / EBITDA INR 1,304 Mn 3.9x Adjusted EPS Dividend Per Share INR 14.6 / Share INR 2.0 / Share 1. Adjusted debt inclu

  27. Slide 27: Experienced Board and Management team

    Experienced Board and Management team High engagement on areas of strategic focus Arun Kumar Deepak Vaidya Sangita Reddy Founder, Group CEO and MD Non-Executive Chairman Independent Director Bharat Shah S. Sridhar Homi R Khusrokhan Independent Independent Director Independent Director Director Badre

  28. Slide 28: Thank You

    Thank You

Strides Pharma Science — Investor Presentation (November 2018) on 6ix